Tdspharm
464280.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.56B
Close$
$2438.52
56.4% downside
Current Fair Value
56.4% downsideOvervalued by 56.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.56 Billion |
|---|---|
| Enterprise Value | $40.76 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $808 |
| Beta | 0.32 |
| Outstanding Shares | 5,288,500 |
Return
| Return on Equity | 11.48% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 12.60% |
Valuation & Multiples
| P/E Ratio | 5.74 |
|---|---|
| PEG | 49.28 |
| Price to Sales | 0.9 |
| Price to Book Ratio | 0.66 |
| Enterprise Value to Revenue | 1.24 |
| Enterprise Value to EBIT | 7.18 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tdspharm
96 employees
CEO: Cheol-Jun Kim Established on November 11, 2002, TDS Pharm Co. Ltd. is headquartered in Seongnam-si, South Korea, and specializes in the creation and manufacturing of transdermal drug delivery solutions. Their offerings include items such as cataplasma...